



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Enocitabine

Item No. 36538

CAS Registry No.: 55726-47-1

Formal Name: N-(1-β-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-docosanamide

Synonyms: Behenoyl-ara-C,
N⁴-Behenoyl-1-β-D-arabinofuranosylcytosine,
behenoyl Cytarabine, NSC 239336

MF: C₃₁H₅₅N₃O₆


FW: 565.8

Purity: ≥95%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Enocitabine is supplied as a solid. A stock solution may be made by dissolving the enocitabine in the solvent of choice, which should be purged with an inert gas. Enocitabine is slightly soluble in methanol (warmed), DMSO (warmed), and tetrahydrofuran (warmed).

Description

Enocitabine is a lipophilic prodrug form of the nucleoside analog cytarabine (Item No. 16069) that contains a docosanoic acid (Item No. 9000338) moiety.¹ It is resistant to deamination by cytidine deaminase.² Enocitabine reduces the virus yield in the supernatant of CMV-infected Vero cells (EC₉₀ = 0.5 μg/ml) and inhibits viral DNA synthesis when used at a concentration of 5 μg/ml.³ It increases survival in an L1210 murine skin lymphocytic leukemia model in a dose-dependent manner.² Formulations containing enocitabine have been used in the treatment of acute myeloid leukemia (AML).

References

1. Higashigawa, M., Ochiai, H., Ohkubo, T., *et al.* Incorporation of N⁴-behenoil-1-β-D-arabinofuranosylcytosine into DNA as 1-β-D-arabinofuranosylcytosine. *Med. Oncol. Tumor Pharmacother.* **5(4)**, 265-271 (1988).
2. Aoshima, M., Tsukagoshi, S., Sakurai, Y., *et al.* N⁴-Behenoil-1-β-D-arabinofuranosylcytosine as a potential new antitumor agent. *Cancer Res.* **37(8 Pt. 1)**, 2481-2486 (1977).
3. Nakamura, K., Eizuru, Y., Kumura, K., *et al.* Antiviral effect of antileukemic drugs N⁴-behenoil-1-beta-D-arabinofuranosylcytosine (BH-AC) and 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine (cyclo-C) against human cytomegalovirus. *J. Med. Virol.* **31(2)**, 141-147 (1990).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/20/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM